Joseph Koopmeiners
· Mayo Professor and Division HeadUniversity of Minnesota · Biostatistics & Health Data Science
Active 2005–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Joseph Koopmeiners, PhD, is the Mayo Professor and Division Head of the Division of Biostatistics & Health Data Science at the University of Minnesota School of Public Health. He develops statistical methods to improve the accuracy and efficiency of questions related to cancer prevention, detection, and treatment. His research combines statistical methods in biomarker validation and Bayesian adaptive methods for clinical trials, with a focus on collaborations within the University of Minnesota Masonic Cancer Center. His work includes developing methods for detecting prostate cancer using MRI, tobacco regulatory science, and early phase cancer clinical trials. Dr. Koopmeiners holds a PhD in Biostatistics from the University of Washington and an MS in Biostatistics from the University of Minnesota. He also earned a BA in Mathematics from St. John's University. He is a member of professional associations such as the American Statistical Association, the International Biometrics Society, and the Society for Clinical Trials. In addition to his research, he teaches in the Biostatistics program, advising master's and PhD students, and courses include Clinical Trials: Design, Implementation, and Analysis. He is also a member of the Masonic Cancer Center and serves as Scientific Co-director of the RapidEVAL Program at the Center for Learning Health Systems Sciences.
Research topics
- Medicine
- Internal medicine
- Pathology
- Immunology
- Gastroenterology
- Anesthesia
- Pediatrics
- Emergency medicine
Selected publications
The Lancet Infectious Diseases · 2022 · 192 citations
BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. METHODS: In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19…
Annals of Internal Medicine · 2022 · 68 citations
Background: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. Objective: To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of endogenous neutralizing antibody (nAb) at study entry than in those with antibodies, especially if viral…
EClinicalMedicine · 2021 · 67 citations
BACKGROUND: The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. Treatment with angiotensin receptor blockers (ARBs), such as losartan, may mitigate these effects, though induction of ACE2 could increase viral entry, replication, and worsen disease. METHODS: This study represents a placebo-controlled blinded randomized clinical trial (RCT) to test the efficacy of losartan on outpa…
Annals of Internal Medicine · 2022 · 61 citations
BACKGROUND: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of COVID-19. OBJECTIVE: To evaluate whether levels of plasma antigen can predict short-term clinical outcomes and identify clinical and viral factors associated with plasma antigen levels in hospitalized patients with SARS-CoV-2. DESIGN: Cross-sectional study of baseline plasma antigen level from 2540 participants enrolled in t…
Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury
JAMA Network Open · 2022 · 56 citations
Importance: SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in preclinical models, although data in humans with COVID-19 remain mixed. Objective: To test the efficacy of losartan to reduce lung injury in hospitalized patients with COVID-19. Design, Setting, and Participants: This blinded, placebo-controlled randomized clinical trial was conducted in 13 hospitals in the United Sta…
Recent grants
Innovative Statistical Methods for Estimating the Impact of Tobacco Product Standards
NIH · $2.4M · 2018–2030
Evaluating New Nicotine Standards for Cigarettes
NIH · $126.0M · 2011–2025
NIH · $229k · 2016–2019
Frequent coauthors
- 55 shared
Dorothy K. Hatsukami
- 53 shared
Claudia A. Salinas
Boehringer Ingelheim (Germany)
- 52 shared
Jennifer W. Tidey
Brown University
- 52 shared
Stephen C. Schmechel
- 50 shared
Eric C. Donny
Wake Forest University
- 43 shared
Janet L. Stanford
- 41 shared
Elaine A. Ostrander
National Institutes of Health
- 38 shared
Erika M. Kwon
Education
- 2004
MS, Biostatistics
University of Minnesota
Awards & honors
- Delta Omega, Honorary Society in Public Health
- Member, Masonic Cancer Center (MCC)
- Scientific Co-director, RapidEVAL Program, Center for Learni…
Similar researchers at University of Minnesota
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Joseph Koopmeiners
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup